только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 11 / 12
Страница 1 / 1

Литература

  1. Адлер Г. Болезнь Крона и язвенный колит. Москва : ГЭОТАР-Мед, 2001. 527 с.
  2. Алекберова З.С. Болезнь Бехчета. Москва, 2007.
  3. Алекберова З.С., Танковский В.Э., Елонаков А.В. Применение инфликсимаба при болезни Бехчета (собственные наблюдения) // РМЖ. 2005. № 13 (24). С. 1595.
  4. Бадокин В.В. Псориатический артрит: клиника, диагностика, лечение : дис. ... д-ра мед. наук, Москва, 2003.
  5. Бадокин В.В., Корсакова Ю.Л., Барскова В.Г. и др. Терапия псориатического артрита инфликсимабом // Современная ревматология. 2009. № 3 (1). С. 29–35.
  6. Бекетова Т.В. АНЦА-ассоциированные системные васкулиты / под ред. Е.Л. Насонова. Москва, 2012.
  7. Бекетова Т.В., Коновалов Р.Н. Синдром Сусака (ретино-кохлео-церебральная васкулопатия) // Научно-практическая ревматология. 2018. Т. 56, № 2. С. 249–252. DOI: https://doi.org/10.14412/1995-4484-2018-249-252
  8. Бекетова Т.В., Ушакова М.А, Никишина Н.Ю. и др. Опыт применения ингибитора интерлейкина 6 тоцилизумаба для лечения гигантоклеточного артериита с тяжелой коморбидной патологией // Научно-практическая ревматология. 2018. Т. 56, № 2. С. 228–234.
  9. Бунчук Н.В. Гигантоклеточный артериит и ревматическая полимиалгия. Москва, 1992.
  10. Годзенко А.А., Бочкова А.Г., Румянцева О.А. и др. Влияние сульфасалазина на течение увеита у больных анкилозирующим спондилитом // Научно-практическая ревматология. 2016. Т. 54, № 1. С. 33–37.
  11. Годзенко А.А., Бочкова А.Г., Румянцева О.А. и др. Влияние терапии ингибиторами фактора некроза опухоли á на частоту обострений увеита у больных анкилозирующим спондилитом // Научно-практическая ревматология. 2014. Т. 52, № 1. С. 27–30.
  12. Годзенко А.А., Бочкова А.Г., Румянцева О.А. и др. Течение и исходы увеита у больных анкилозирующим спондилитом // Научно-практическая ревматология. 2014. Т. 52, № 5. С. 520–525. DOI: https://doi: 10.14412/1995-4484-2014-520-525.
  13. Годзенко А.А., Разумова И.Ю., Бочкова А.Г. и др. Клиническая оценка увеита и ее значение в диагностике спондилоартритов // Научно-практическая ревматология. 2011. Т. 49, № 6. С. 38–42.
  14. Ермакова Н.А. Классификация и клиническая оценка увеитов // Клиническая офтальмология. 2003. № 4. С. 146–149.
  15. Ермакова Н.А., Алекберова З.С., Решетняк Т.М. и др. Ретинальный васкулит при системной красной волчанке и вторичном антифосфолипидном синдроме // Вестник офтальмологии. 2005. Т. 121, № 5. С. 31–36.
  16. Кацнельсон Л.А., Танковский В.Э. Увеиты (клиника, лечение). Москва : 4-й филиал Воениздата, 2003. 286 с.
  17. Корсакова Ю.Л., Коротаева Т.В., Логинова Е.Ю. и др. Распространенность коморбидных и сопутствующих заболеваний при псориатическом артрите по данным Общероссийского регистра больных псориатическим артритом // Научно-практическая ревматология. 2021. Т. 59, № 3. С. 275–281. DOI: https://doi.org/10.47360/1995-4484-2021-275-281
  18. Кузин А.В., Лоранская И.Д., Степанова Е.В. Ревматологические проявления воспалительных заболеваний кишечника : учебное пособие. Москва, 2019. 56 с.
  19. Насонов Е.Л. Антифосфолипидный синдром. Москва : Литтерра, 2004.
  20. Насонов Е.Л., Денисов Н.Л., Станислав М.Л. Интерлейкин-17 — новая мишень для антицитокиновой терапии иммуновоспалительных ревматических заболеваний // Научно-практическая ревматология. 2013. Т. 51, № 5. С. 545–552.
  21. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит // Ревматология : национальное руководство / под ред. Е.Л. Насонова, В.А. Насоновой. Москва : ГЭОТАР-Медиа, 2008. С. 290–331.
  22. Панова И.Е., Дроздова Е.А. Увеиты : руководство для врачей. Москва : МИА, 2014. 144 с.
  23. Российские клинические рекомендации. Ревматология / под ред. Е.Л. Насонова. Москва : ГЭОТАР-Медиа, 2017. 456 с.
  24. Салугина С.О., Катаргина Л.А., Старикова А.В. Ревматические заболевания и поражение глаз у детей // Научно-практическая ревматология. 2004. Т. 42, № 1. С. 78–81.
  25. Смирнова Т.В Глазные проявления антифосфолипидного синдрома : автореф. дис. ... канд. мед. наук. Москва, 2008.
  26. Эрдес Ш.Ф., Бадокин В.В., Бочкова А.Г. и др. О терминологии спондилоартритов // Научно-практическая ревматология. 2015. Т. 53, № 6. С. 657–660.
  27. Abbouda А. et al. Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features // Semin. Ophthalmol. 2017. Vol. 32, N 6. P. 715–720. DOI: https://doi.org/10.3109/08820538.2016.1170161
  28. Al Rashidi S., Al Fawaz A., Kangave D. et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab // Ocul. Immunol. Inflamm. 2013. Vol. 21. P. 468–474. DOI: https://doi.org/10.3109/09273948.2013.779727
  29. Ali A., Ku J.H., Suhler E.B. et al. The course of retinal vasculitis // Br. J. Ophthalmol. 2014. Vol. 98, N 6. P. 785–789.
  30. Angeles-Han S.T., Ringold S., Beukelman T., Lovell D. et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Rheumatol. 2019. Vol. 71, N 6. P. 864–877. DOI: https://doi.org/10.1002/art.40885 Epub 2019 Apr 25. PMID: 31021511.
  31. Bachta A., Kisiel B., Thistochowicz M. et al. High efficacy of methotrexate in patients with recurrent idiopathic acute anterior uveitis: a prospective study // Arch. Immunol. Ther. Exp. (Warsz.). 2017. Vol. 65, N 1. P. 93–97.
  32. Bandini F., Benedetti L., Ceppa P., Corallo G. Uveitis as a presenting sign of giant cell arteritis // J. Neurophthalmol. 2005. Vol. 25, N 3. P. 247–248.
  33. Bănicioiu-Covei S., Vreju A., Ciurea P. Correlations between infection patterns and eye damage in reactive arthritis // Rom. J. Morphol. Embryol. 2019. Vol. 60, N 2. P. 601–604.
  34. Benitez-Del-Castillo J.M., Carcia-Sanchez J., Iradier T., Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis // Eye (London). 2000. Vol. 14, N 3A. P. 340–343.
  35. Braun J., Baraliakos X., Deodhar A. et al. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study // Ann. Rheum. Dis. 2017. Vol. 76, N 6. P. 1070–1077.
  36. Braun J., Baraliakos X., Listing J., Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. // Arthritis Rheum. 2005. Vol. 52, N 8. P. 2447–2451.
  37. Braun J., van den Berg R., Baraliakos X. et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis // Ann. Rheum. Dis. 2011. Vol. 70, N 6. P. 896–904.
  38. Brewerton D.A., Caffrey M., Nicholls A. et al. Acute anterior uveitis and HL-A27 // Lancet. 1974. Vol. 302, N 7836. P. 994-996. DOI: https://doi.org/10.1016/s0140-6736(73)91o990-8
  39. Brito-Zeron P., Herez-Alvarez R., Ramos-Casals M. et al. Etanercept and uveitis: friends or foes? // Curr. Med. Res. Opin. 2015. Vol. 31, N 2.
    P. 251–252.
  40. Bubová K., Gregová M., Zegzulková K. et al. Active sacroiliitis on magnetic resonance imaging in patients with anterior uveitis // Ann. Rheum. Dis. 2019. Vol. 78, N 2. P. A470. DOI: https://doi.org/10.1136/annrheumadis-2019-eular7439
  41. Calvo-Rio V., Blanco R., Beltran E. et al. Anti-TNF-therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients // Rheumatology. 2014. Vol. 53. P. 2223–2231. DOI: https://doi.org/10.1093/rheumatology/keu266
  42. Calvo-Río V., Gonzales-Gay M.A. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients // Semin. Arthritis Rheum. 2016. Vol. 46, N 1. P. 95–101.
  43. Cao Y., Zhang W., Wu J. et al. Peripheral ulcerative keratitis associated with autoimmune disease: pathogenesis and treatment // J. Ophthalmol. 2017. Vol. 2017. Article ID 7298026.
  44. Cekic S., Yalcinbayir O., Kilic S.S. Ocular involvement in muckle-wells syndrome // Ocul. Immunol. Inflamm. 2020. Vol. 28, N 1. P. 70–78. DOI: https://doi.org/10.1080/09273948.2018.1552305
  45. Charlton R., Green A., Shaddick G. et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study // Ann. Rheum. Dis. 2018. Vol. 77. P. 277–280.
  46. Chen A., Chen H., Hwang Y. et al. Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: a cross-sectional analysis // Medicine (Baltimore). 2016. Vol. 95. P. e4218.
  47. Chen B., Li L., He Ch., Li D. et al. HLA-B27 in the pathogenesis of ankylosing spondylitis // Mol. Med. Rep. 2017. Vol. 15, N 4. P. 1943–1951. DOI: https://doi.org/10.3892/mmr 2017.6248
  48. Chung Y.M., Liao H.T., Lin K.C. et al. Prevalence of spondyloarthritis in 504 Chinese patients with HLA-B27-associated acute anterior uveitis // Scand. J. Rheumatol. 2009. Vol. 38, N 2. P. 84–90. DOI: https://doi.org/10.1080/03009740802385423
  49. Coates L.C., MacGonagle D.G., Bennett A. et al. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis // Ann. Rheum. Dis. 2008. Vol. 67, N 5. P. 729–730.
  50. Cobo-Ibáñez T., del Carmen Ordonez M., Munoz-Fernandez S. et al. Do TNF-blockers reduce or induce uveitis? // Rheumatology (Oxford). 2008. Vol. 47, N 5. P. 731–732.
  51. Cobo-Soriano R., Sanchez-Ramon S., Aparicio M.J. et al Antiphospholipid antibodies and retinal thrombosis in patients without risk factors // Am. J. Ophthalmol. 1999. Vol. 128. P. 725–732.
  52. Colbert R. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum? // Mol. Med. Today. 2000. Vol. 6, N 6. P. 224–230. DOI: https://doi.org/10.1016/s1357-4310(00)01699-3
  53. Colbert R.A., Tran T.M., Layh-Schmit G. HLA-B27 misfolding and ankylosing spondylitis // Mol. Immunol. 2014. Vol. 57, N 1. P. 44–51. DOI: https://doi.org/10.1016/molimm 2013 07.013
  54. Conway R.M., Graham S.L., Lasser M. Incomplete Reiters syndrome with focal involvement of the posterior segment // Aust. N. Z. J. Ophthalmol. 1995. Vol. 23, N 1. P. 63–66.
  55. Coyle E.F. Scleroderma of the cornea // Br. J. Ophthalmol. 1956. Vol. 40, N 4. P. 239–241. DOI: https://doi.org/10.1136/bjo.40.4.239.24
  56. Craig J.P., Nelson J.D., Azar D.T. et al. TFOS DEWS II report executive summary // Ocul. Surf. 2017. Vol. 15. P. 802–812.
  57. Dammaccо R. Systemic lupus erythematosus and ocular involvement: an overview // Clin. Exp. Med. 2018. Vol. 18. P. 135–149. DOI: https://doi.org/10.1007/s10238-017-0479-9
  58. Davatchi F., Shams H., Rezaipoor M. et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study) // Int. J. Rheum. Dis. 2010. Vol. 13, N 3. P. 246–252.
  59. Davis J.C., Van der Heijde D., Braun J. et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial // Arthritis Rheum. 2003. Vol. 48, N 11. P. 3230–3236.
  60. De Jesus A.A., Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations // Clin. Immunol. 2013. Vol. 147, N 3. P. 155–174. DOI: https://doi.org/10.1016/j.clim.2013.03.016
  61. de la Maza M.S., Molina N., Gonzalez-Gonzalez L.A. et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis // Ophthalmology. 2012. Vol. 119. P. 43–50.
  62. Dejaco C., Singh Y.P., Perel P. et al.; European League Against Rheumatism; American College of Rheumatology. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism American College of Rheumatology collaborative initiative // Arthritis Rheumatol. 2015. Vol. 67, N 10. P. 2569-2580. DOI: https://doi.org/10.1002/art.39333
  63. Demirci F.Y., Kucukkaya R., Akarcay K. et al. Ocular involvement in APS // Int. Ophthalmol. 1998. Vol. 22. P. 323–329.
  64. Diaz-Liopis M., García-Delpech S., Salom D. Adalimumab therapy for refractory uveitis: a pilot study // J. Ocul. Pharmacol. Ther. 2008. Vol. 24, N 3. P. 351–361.
  65. Dick A.D., Tugal-Tutkun I., Foster S. et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials // Ophthalmology. 2013. Vol. 120. P. 777–787. DOI: https://doi.org/10.1016/j.ophtha.2012.09.040
  66. Dion J., Leroux G., Mouthon L. et al. Relapsing polychondritis: what’s new in 2017? // Rev. Med. Interne. 2018. Vol. 39, N 6. P. 400–407. DOI: https://doi.org/10.1016/j.revmed.2017.07.008 Epub 2017 Sep 8.
  67. Doctor P., Sultan A., Syed S. et al. Infliximab for the treatment of refractory scleritis // Br. J. Ophthalmol. 2010. Vol. 94. P. 579–583.
  68. Dodd E.M., Lowder C.Y., Meisler D.M. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics // Ocul. Immunol. Inflamm. 1999. Vol. 7, N 2. P. 85–92.
  69. Dode C., Le Du N., Cuisset L. et al. New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes // Am. J. Hum. Genet. 2002. Vol. 70, N 6. P. 1498–1506.
  70. Dong H., Li Q., Zang Y. et al. IL23R gene confers susceptibility to ankylosing spondylitis concomitant with uveitis in a Han Chinese population // PLoS One. 2013. Vol. 8, N 6. Article ID e67505. DOI: https://doi.org//10.1371/journal.pone0067505
  71. Dougados M. et al. [Prevention of acute anterior uveitis associated with spondylarthropathy induced by salazosulfapyridine] // Rev. Rhum. Ed. Fr. 1993. Vol. 60, N 1. P. 81–83.
  72. Durrani K., Foster C.S. Psoriatic uveitis: a distinct clinical entity? // Am. J. Ophthalmol. 2005. Vol. 139, N 1. P. 106–111.
  73. Durrani O.M., Gordon C., Murray P.I. Primary antiphospholipid syndrome: current concepts // Surv. Ophthalmol. 2002. Vol. 47. P. 215–238.
  74. Ebringer A., Baines V., Ziff M. et al. Ethiopathogenesis of ankylosing spondylitis and the cross-tolerance hypothesis // Advances in Inflammation Research. Vol. 9. The Spondyloarthropathies. New York, NY : Raven Press, 1985. P. 101–128.
  75. El-Shabrawi Y., Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leucocyte antigen B27-associated acute anterior uveitis // Ophthalmology. 2002. Vol. 109, N 12. P. 2342–2346.
  76. Emilie D., Liozon E., Crevon M.C. et al. Production of interleukin 6 by granulomas of giant cell arteritis // Hum. Immunol. 1994. Vol. 39. P. 172. DOI: https://doi.org/10.1016/0198-8859(94)90096-5
  77. Feltkamp T.E.W., Verjans Y.M. The pathogenesis of HLA-B27 associated diseases // XIII European Congress of Rheumatology «Rheumatology in Europe». 1995. Suppl. 2. Vol. 24. P. 45–47.
  78. Fernández-Melón J., Muñoz-Fernández S., Hidalgo V. et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies // J. Rheumatol. 2004. Vol. 31, N 3. P. 524–527.
  79. Fortney A.C., Chodosh J. Conjunctival ulceration in recurrent Wegener granulomatosis // Cornea. 2002. Vol. 21, N 6. P. 623–624.
  80. Fussell H., Nesbeth D., Lenart I. et al. Novel detection of in vivo HLA-B27 conformations correlates with ankylosing spondylitis association // Arthritis Rheum. 2008. Vol. 58, N 11. P. 3419–3424. DOI: https://doi.org/10.1002/art23990
  81. Galor A., Thorne J.E. Scleritis and peripheral ulcerative keratitis // Rheum. Dis. Clin. North Am. 2007. Vol. 33. P. 835–854.
  82. Gangaputra S., Newcomb C.V., Liesegang N.L. et al. Methotrexate for ocular inflammatory diseases // Ophthalmology. 2009. Vol. 116, N 11. P. 2188–2198.
  83. Gaubitz M., Lübben B. Cogan’s syndrome: organ-specific autoimmune disease or systemic vasculitis? A report of two cases and review of the literature // Clin. Exp. Rheumatol. 2001. Vol. 19. P. 463–469.
  84. Gelfand Y.A., Dori D., Miller B., Brenner B. Visual disturbances and pathologic ocular findings in primary antiphospholoipid syndrome // Ophthalmology. 1999. Vol. 106. P. 1537–1540.
  85. Genevois O., Calenda E., Nasser Z. et al. Hypopyon uveitis (without scleritis) a manifestation symptom of relapsing polychondritis // Ann. Ophthalmol. (Skokie). 2009. Vol. 41, N 3–4. P. 208–211.
  86. Giannini E.H., Brewer E.J., Kuzmina N.N. Metotrexate in resistant rheumatoid arthritis. Results of USA-USSR double-blind placebo control trial // N. Engl. J. Med. 1992. Vol. 326. P. 1043–1010.
  87. Godzenko A., Razumova I., Guseva I. The probability of spondylоarthritis in patients with uveitis // Ann. Rheum. Dis. 2020. Vol. 79, N 1. P. 1635.
  88. Goldbach-Mansky R., Dailey N.J., Canna S.W. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition // N. Engl. J. Med. 2006. Vol. 355, N 6. P. 581–92.
  89. Goto K., Ota M., Maksymowych W.P. et al. Association between MIC A gene A4 allele and acute anterior uveitis in white patients with and without HLA-B27 // Am. J. Pphthalmol. 1998. Vol. 126, N 3. P. 436–441. DOI: https://doi.org/10.1016/s002.9394(98)00100-7
  90. Gouveia E., Elmann D., Morales M.S. Ankylosing spondylitis and uveitis: overview // Rev. Bras. Reumatol. 2012. Vol. 52, N 5. P. 742–756.
  91. Griger Z., Danko K., Nemeth G. et al. Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis // Int. J. Ophthalmol. 2020. Vol. 13, N 9. P. 1443–1450. DOI: https://doi.org/10.18240/ijo.2020.09.17
  92. Grygiel-Górniak B., Puszczewicz M., Czaplicka E. Susac syndrome — clinical insight and strategies of therapy // Eur. Rev. Med. Pharmacol. Sci. 2015. Vol. 19, N 9. P. 1729–1735.
  93. Guedes M.C., Borrego L.M., Proença R.D. Roles of interleukin 17 in uveitis // Indian J. Ophthalmol. 2016. Vol. 64, N 9. P. 628–634.
  94. Guignard S., Gossec L., Salliot C. et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study // Ann. Rheum. Dis. 2006. Vol. 65, N 12. P. 1631–1663.
  95. Guignier B., Messer L., Subilia A., Michel G. [Inaugural bilateral panuveitis in relapsing polychondritis] // Fr. J. Ophtalmol. 2010. Vol. 3, N 10. P. 741–743.
  96. Gupta A., Monroy D., Ji Z., et al. Transforming growth factor beta-1 and beta-2 in human tear fluid // Curr. Eye Res. 1996. Vol. 15. P. 605–614.
  97. Hale S., Lightman S. Anti-TNF therapies in management of acute and chronic uveitis // Cytokine. 2006. Vol. 33, N 4. P. 231–237.
  98. Haller-Schober E.M., El-Shabravi Y. Chlamidial conjunctivitis (in adults), uveitis, and reactive arthritis, including SARA. Sexually acquired reactive arthritis // Best Pract. Res. Clin. Obstet. Gynaecol. 2002. Vol. 16, N 6. P. 815–828.
  99. Handa T., Tsunekawa H., Yoneda M. et al. Long-term remission of ocular and extraocular manifestations in Behcet’s disease using infliximab // Clin. Exp. Rheumatol. 2011. Vol. 29, N 4. Suppl. 67. P. S58–S63.
  100. Hannum C.H., Wilcox C.J., Arend W.P. et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor // Nature 1990. Vol. 343. P. 336–340.
  101. Haroon M., O’Rourke M., Ramasamy P. et al. A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool) // Ann. Rheum. Dis. 2015. Vol. 74, N 11. P. 1990–1995. DOI: https://doi.org/10.1136/annrheumdis-2014-205358 Epub 2014 Jun 13.
  102. Harper S.L., Letko E., Samson C.M. et al. Wegener’s granulomatosis: the relationship between ocular and systemic disease // J. Rheumatol. 2001. Vol. 28, N 5. P. 1025–1032.
  103. Hatemi G., Christensen R., Bang D. et al. 2018 update of the EULAR recommendations for the management of Behcet’s syndrome // Ann. Rheum Dis. 2018. Vol. 77, N 6. P. 808–818. DOI: https://doi.org/10.1136/annrheumdis-2018-213225
  104. Hayreh S., Podhajsky P., Zimmerman B. Ocular manifestations of giant cell arteritis // Am. J. Ophthalmol. 1998. Vol. 125, N 4. P. 509–520.
  105. Heiligenhaus A., Minden A., Tappeiner C. Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis // Semin. Arthritis Rheum. 2019. Vol. 49, N 1. P. 43–55. DOI: https://doi.org/10.1016/j.semarthrit.2018.11.004 Epub 2018 Dec 4.
  106. Heiligenhaus A., Mingels A., Heinz C. et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication // Eur. J. Ophthalmol. 2007. Vol. 17. P. 743–748.
  107. Heslinga S.C., Nurmohamed M., Gerards A.H. et al. SAT0416 significantly reduced recurrence rate of acute anterior uveitis in ankylosing spondylitis during treatment with golimumab // Ann. Rheum. Dis. 2016. Vol. 75, N 2. P. 820–821.
  108. Hickman R.A., Denniston A.K., Yee C.S. et al. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy // Lupus. 2010. Vol. 19, N 3. P. 327–329.
  109. Holland E.J. Intranasal tear neurostimulation for subjects with dry eye disease: results from 2 pivotal clinical trials // Presented at American Academy of Ophthalmology Annual Meeting. New Orleans, 2017.
  110. Huang J.L., Hung I.J., Hsieh K.H. Sulphasalazine therapy in chronic uveitis of children with chronic arthritis Asian Pac // J. Allergy Immunol. 1997. Vol. 15. P. 71–75.
  111. Hueber W., Patel D.D., Dryja T. et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis // Sci. Transl. Med. 2010. Vol. 52, N 2. P. 52ra72.
  112. Huerva V., Ascaso F.J., Grzybowski A. Infliximab for peripheral ulcerative keratitis treatment // Medicine (Baltimore). 2014. Vol. 93. P. 176.
  113. Huhtinen M., Karma A. HLA-B27 typing in the categorization of uveitis in a HLA-B27 rich population // Br. J. Ophthalmol. 2000. Vol. 84, N 4. P. 413–416.
  114. Huong D.L.T., Tran T.H.C., Piette J.C. Granulomatous uveitis revealing Wegener’s granulomatosis // J. Rheumatol. 2006. Vol. 33. P. 1209–1210.
  115. Iliescu D.A., Timaru C.M., Batras M. et al. Cogan’s syndrome // Rom. J. Ophthalmol. 2015. Vol. 59, N 1. P. 6–13.
  116. International Team for the Revision of the International Criteria for Behcet’s Disease (ITR-ICBD). The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria // J. Eur. Acad. Dermatol. Venereol. 2014. Vol. 28, N 3. P. 338–347. DOI: https://doi.org/10.1111/jdv.12107
  117. Jabs D.A. et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop // Am. J. Ophthalmol. 2005. Vol. 140, N 3. P. 509–516.
  118. Jennette J.C., Falk R.J., Bacon P.A. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides // Arthritis Rheum. 2013. Vol. 65. P. 1–11.
  119. Kacmaz R.O. Cyclosporine for ocular inflammatory disease // Ophthalmology. 2010. Vol. 117, N 3. P. 576–584.
  120. Kakkassery V., Mergler S., Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment // Curr. Eye Res. 2010. Vol. 35, N 8. P. 751–756.
  121. Kalogeropoulos C.D., Spyron P., Stefanioton M.I. et al. Anticardiolipin antibodies and occlusive vascular disease of the eye: prospective study // Doc. Ophthalmol. 1998. Vol. 95. P. 109–120.
  122. Karampatakis V., Karamitsos A., Skriapa A., Pastiadis G. Comparison between normal values of 2- and 5-minute Schirmer test without anesthesia // Cornea. 2010. Vol. 29. P. 497–501.
  123. Killian М., Touraine R., Amouzougan A. et al. Impact of genetic predisposition of de novo uveitis with etanercept in ankylosing spondylitis // Ann. Rheum. Dis. 2015. Vol. 74, N 3. P. e22.
  124. Kim M., Sim Y., Choi S., Park Y. Potential predictors for frequent relapse in human leukocyte antigen-B27-associated uveitis // Graefes Arch. Clin. Exp. Ophthalmol. 2018. Vol. 256, N 8. P. 1543–1549. DOI: https://doi.org/10.1007/s00417-018-4002-0
  125. Kim T.J., Na K., Lee B., Kim T.H. HLA-B27 homozygosity no influence on clinical manifestations and functional disability in ankylosing spondytis // Clin. Exp. Rheumatol. 2009. Vol. 27, N 4. P. 574–579.
  126. Kiss S., Letko E., Qamruddin S. Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter’s syndrome // Ophthalmology. 2003. Vol. 110, N 9. P. 1764–1769.
  127. Knickelbein J.E., Tucker W.R., Bhatt N. et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial // Am. J. Ophthalmol. 2016. Vol. 172. P. 104–110.
  128. Kostik M.M., Gaidar E.V., Hynnes A.Y. et al. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use // Clin. Exp. Rheumatol., 2016. Vol. 34. P. 714–718.
  129. Kovalev Iu.N., Ilin I.I. Ophthalmological aspects of Reiter’s disease // Vestn. Ophthalmol. 1990. Vol. 106, N 4. P. 65–69.
  130. Kraus C.L., Culican S.M., Use of biologic agents in ocular manifestations of rheumatic disease // Int. J. Rheumatol. 2012. Vol. 2012. Article ID 203819.
  131. Kubal A.A., Perez V.L. Ocular manifestations of ANCA-associated vasculitis // Rheum. Dis. Clin. North Am. 2010; 36(3): 573–586.
  132. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R. et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes // Ann. Rheum. Dis. 2011. Vol. 70, N 12. P. 2095–2102.
  133. Kvien T.K., Hoyeraal H.M., Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study // J. Rheumatol. 1986. Vol. 13. P. 118–123.
  134. Lambert J.R., Wright V. Eye inflammation in psoriatic arthritis // Ann. Rheum. Dis. 1976. Vol. 35, N 4. P. 354–356.
  135. Lee J.T., Yates W.B., Rogers S. et al. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis [Electronic resource] // Br. J. Ophthalmol. 2018. Vol. 102, N 12. P. 1672–1678. URL: http://bjo.bmj.com/content/early/2018/02/18/bjophthalmol-2017-311234
  136. Lepore L., Paloni G., Caorsi R. et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra // J. Pediatr. 2010. Vol. 157, N 2. P. 310–315.e1.
  137. Letko E., Yeh S., Foster G.S. et al Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive // Ophthalmology. 2015. Vol. 122, N 5. P. 939–948.
  138. Levinson R., Martin T., Luo L. et al. Killer cell immunoglobulin-like receptors in HLA-B27-associated acute anterior uveitis, with and without axial pondyloarthropathy // Invest. Ophthalmol. Vis. Sci. 2010. Vol. 51, N 3. P. 1505–1510. DOI: https://doi.org/10.1167/iovs.09-4232 Epub 2009 Oct 22.
  139. Levy-Clarke G., Jabs D.A., Read R.W. et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders // Ophthalmology. 2014. Vol. 121, N 3. P. 785–796.e783.
  140. Lie E., Lindstrom U., Zverkova-Sandstrom T. et al. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register // Ann. Rheum. Dis. 2017. Vol. 76, N 9. P. 1515–1521.
  141. Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do Tumor necrosis factor inhibitors cause uveitis? A registry-based study // Arthritis Rheum. 2007. Vol. 56, N 10. P. 3248–3252.
  142. Little J.A., Sen E.S., Strike H. et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood // J. Rheumatol. 2014. Vol. 41. P. 136–139.
  143. Lyons J.L., Rosenbaum J.T. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy // Arch. Ophthalmol. 1997. Vol. 115, N 1. P. 61–64.
  144. Magro C.M., Poe J.C., Lubow M. et al. Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies // Am. J. Clin. Pathol. 2011. Vol. 136. P. 903–912.
  145. Manjeet S.B, Gondal I., Amarnani A. et al. Ocular manifestations of rheumatoid arthritis: implications of recent clinical trials // Int. J. Clin. Res. Trials. 2019. Vol. 4, N 2. P. 139. DOI: https://doi.org/10.15344/2456-8007/2019/139
  146. Marrani E., Paganelli V., de Libero C. et al. Long-term efficacy of abatacept in pediatric patients with idiopathic uveitis: a case series // Graefes Arch. Clin. Exp. Ophthalmol. 2015. Vol. 253. P. 1813–1816.
  147. Martin T.M., Kurz D.E., Rosenbaum J.T. Genetics of uveitis // Ophthalmol. Clin. North Am. 2003. Vol. 16, N 4. P. 555–565. DOI: https://doi.org/10.1016/s0896-1549(03)00071-3
  148. Martin T.М., Zhang G., Luo J. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease // Arthritis Rheum. 2005. Vol. 52, N 1. P. 269–274.
  149. Mathews J.D., Granford B.A., Bigell J.L., Mackay I.B. et al. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial // Br. J. Ophthalmol. 1969. Vol. 53, N 5. P. 327–330.
  150. McGonagle D., Stockwin L., Isaacs J. et al. An enthesitis based model for the pathogenesis of spondyloarthropathy. additive effects of microbial adjuvant and biomechanical factors at disease sites // J. Rheumatol. 2001. Vol. 28, N 10. P. 2155–2159.
  151. Mintz R., Feller E.R., Bahr R.L. Ocular manifestations of inflammatory bowel disease // Inflamm. Bowel Dis. 2004. Vol. 10, N 2. P. 135–139.
  152. Mitulescu C., Popescu C., Oprea C. et al. A referable clinical pattern of spondyloarthritis-associated uveitis // Rom. J. Ophthalmol. 2018. Vol. 62, N 2. P. 155–161.
  153. Moll J.М. Rheumatology in Clinical Practice. Oxford : Blackwell Scientific, 1987. 764 p.
  154. Moller P., Berg K. Ankylosing spondylitis is part of multifactorial syndrome: Hereditary Multifocal Relapsing Inflammation (HEMRI) // Clin. Genet. 1984. Vol. 26, N 3. P. 187–194.
  155. Muckle T.J., Wellsm Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome // QJM. 1962. Vol. 31. P. 235–248.
  156. Muñoz-Fernández S., de Miguel E., Cobo-Ibáñez T. et al. Enthesis inflammation in recurrent acute anterior uveitis without spondylarthritis // Arthritis Rheum. 2009. Vol. 60, N 7. P. 1985–1990. DOI: https://doi.org/10.1002/art.24636
  157. Muñoz-Fernández S., Garcia-Aparicio A.M., Hidalgo M.V. et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis // Eye (London). 2009. Vol. 23, N 5. P. 1130–1133.
  158. Muñoz-Fernández S., Idalgo V., Fernandez-Melon J. et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period // J. Rheumatol. 2003. Vol. 30, N 6. P. 1277–1957.
  159. Nair J., Singh T. Sjögren’s syndrome: review of the aetiology, pathophysiology & potential therapeutic interventions // J. Clin. Exp. Dent. 2017. Vol. 9, N 4. P. e584–e589.
  160. Niehues T., Winterhalter S., Zierhut M. et al. EBM analysis: classic DMARDs (disease-modifying antirheumatic drugs) and immunosuppressants in arthritis and uveitis // Klin. Monatsbl. Augenheilkd. 2007. Vol. 224. P. 520–525.
  161. Nossent J., Johnsen S., Bakland G. The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis // Scand. J. Rheumatol. 2016. Vol. 45, N 6. P. 474–479. DOI: https://doi.org/10.3109/03009742.2016.1150507
  162. Ozyazgan Y., Yurdakul S., Yazici H. et al. Low dose cyclosporin. A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial // Br. J. Ophthalmol. 1992. Vol. 76. P. 241–243. DOI: https://doi.org/10.1136/bjo.76.4.241
  163. Paiva E.S., Macaluso D.C., Edwards A. Characterisation of uveitis in patients with psoriatic arthritis // Ann. Rheum. Dis. 2000. Vol. 59. P. 67–70.
  164. Paley M., Karacal H., Rao P. et al. Tofacitinib for refractory uveitis and scleritis // Am. J. Ophthalmol. Case Rep. 2018. Vol. 13. P. 53–55. DOI: https://doi.org/10.1016/j.ajoc.2018.12.001
  165. Papadopoulou C., Kostik M., Böhm M. et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis // J. Pediatr., 2013. Vol. 163. P. 879–884.
  166. Pasadhika S., Kempen J.H., Newcomb C.W. et al. Azathioprine for ocular inflammatory diseases // Am. J. Ophthalmol. 2009. Vol. 148, N 4. P. 500–509.
  167. Pato E. et al. Development of an activity disease score in patients with uveitis (UVEDAI) // Rheumatol. Int. 2017. Vol. 37, N 4. P. 647–656.
  168. Pato E., Bañares A., Jover J.A. et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis // J. Rheumatol. 2000. Vol. 27, N 9. P. 2198–2202.
  169. Postorino E., Rania L., Aragona Е. et al. Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye // Eur. J. Ophthalmol. 2018. Vol. 28, N 1. P. 25–31. DOI: https://doi.org/10.5301/ejo.5001011 Epub 2018 Feb 19.
  170. Pulsatelli L., Boiardi L., Assirelli E. et al. Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study // Clin. Exp. Rheumatol. 2017. Vol. 35, suppl. 103. N 1. P. 102–110.
  171. Raffeiner B., Ornetto F., Bernardi L. et al. Inefficacy or paradoxical effect? Uveitis in ankylosing spondylitis treated with etanercept [Electronic resource] // Case Rep. Med. 2014. Vol. 2014. Article ID 471319. URL: https://www.hindawi.com/journals/crim/2014/471319/
  172. Rajesh C., Cole M. Panuveitis as a presenting feature of giant cell arteritis // Br. J. Ophthalmol. 2000. Vol. 84. P. 337–340.
  173. Ramos-Casals M., Brito-Zerón P., Bombardieri S. et al.; EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies // Ann. Rheum. Dis. 2020. Vol. 79, N 1. P. 3–18. DOI: https://doi.org/10.1136/annrheumdis-2019-216114 Epub 2019 Oct 31.PMID: 31672775.
  174. Razumova I., Godzenko A., Guseva I. Complications of anterior uveitis associated with HLA-B27 antigen in patients with and without spondyloarthritis // Ann. Rheum. Dis. 2019. Vol. 78, N 2. P. A486. DOI: https://doi.org/10.1136/annrheumdis 2019-eular2946
  175. Reiff A., Takei S., Sadeghi S. et al. Etanercept therapy in children with treatment-resistant uveitis // Arthritis Rheum. 2001. Vol. 44. P. 1411–1415.
  176. Říhová E., Svozílková P., Brichová M., Klímová A., Kuthan P., Diblík P. Ocular manifestations of granulomatosis with polyangiitis // Cesk. Slov. Oftalmol. 2019. Vol. 74, N 5. P. 167–174. DOI: https://doi.org/10.31348/2018/5/1
  177. Rivera-Civico F., Jiménez-Alonso J., Martin-Armada M. et al. HLA-B27+ anterior uveitis with or without associated spondyloarthritis: clinical and immunological features // Ann. Rheum. Dis. 1999. Vol. 58, N 11. P. 721–722.
  178. Robinson P., Leo P.J., Pointon J.J. et al. The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis // Genes Immun. 2016. Vol. 17, N 1. P. 46–51. DOI: https://doi.org/10.1038/gene 2015.49
  179. Rodriguez A., Akova Y.A., Pedroza-Seres M. Posterior segment ocular manifestations in patients with HLA-B27-associated uveitis // Ophthalmology. 1994. Vol. 101, N 7. P. 1267–1274.
  180. Rosé C.D., Aróstegui J.I., Martin T.M. NOD2-associated pediatric granulomatous arthritis (PGA), an expanding phenotype: a study of an international registry and national cohort in Spain // Arthritis Rheum. 2009. Vol. 60, N 6. P. 1797–1803.
  181. Rose C.D., Cimaz R., Thomee C. et al. Blau prospective cohort study: articular and ocular outcomes // 17th Congress of ISSAID, International Society of Systemic Auto-Inflammatory Diseases. Lausanne, Switzer-
    land, 2013.
  182. Rosenbaum J., Asquith M. The microbiome and HLA B27-associated acute anterior uveitis // Nat. Rev. Rheumatol. 2018. Vol. 14, N 12. P. 704–713. DOI: https://doi.org/10.1038/s41584-018-0097-2
  183. Rosenbaum J., Sibley C., Lin P. Retinal vasculitis // Curr. Opin. Rheumatol. 2016. Vol. 28, N 3. P. 228–235. DOI: https://doi.org/10.1097/BOR.0000000000000271
  184. Rosenbaum J.T. Characterization of uveitis associated with spondyloarthritis // J. Rheumatol. 1989. Vol. 16, N 6. P. 792–796.
  185. Rosenbaum J.T., Lin P., Asquith M. et al. Does the microbiome play a causal role in spondyloarthritis? // Clin. Rheumatol. 2014. Vol. 33, N 6. P. 763–767. DOI: https://doi.org/10.1007/s10067-014-2664-5
  186. Rudwaleit M., Rodevand E., Holck P. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study // Ann. Rheum. Dis. 2009. Vol. 68, N 5. P. 696–701.
  187. Rudwaleit M., Rosembaum J.T., Landeve R. et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis // Arthritis Care Res. (Hoboken). 2016. Vol. 68, N 6. P. 838–844.
  188. Sainz de la Maza M., Molina N., Gonzalez-Gonzalez L.A. et al. Clinical characteristics of a large cohort of patients with scleritis and episcleritis // Ophthalmology. 2012. Vol. 119. P. 43–50.
  189. Salama A., Elsheikh A., Alweis R. Is this a worrisome red eye? Episcleritis in the primary care setting // J. Community Hosp. Intern. Med. Perspect. 2018. Vol. 8. P. 46–48.
  190. Salvarani C., Cantini F., Boiardi L., Hunder G. Laboratory investigations useful in giant cell arteritis and Takayasu’s arteritis // Clin. Exp. Rheumatol. 2003. Vol.21, N 6. Suppl. 32. P. 23–28.
  191. Samson C., Waheed N., Baltatzis S. et al. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients // Ophthalmology. 2001. Vol. 108, N 6. P. 1134–1139.
  192. Santos S.D., Lynch S., Campbell E.C. et al. Induction of HLA-B27 heavy chain homodimer formation after activation in dendritic cells // Arthritis Res. Ther. 2008. Vol. 10, N 4. P. R100. DOI: https://doi.org/10.1186/ar2492
  193. Schittenhelm R.B., Lim Kam Sian T.C., Wilmann P.G. et al. Revisiting the arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of HLA-B27 allotypes // Arthritis Rheumatol. 2015. Vol. 67, N 3. P. 702–713. DOI: https://doi.org/10.1002/art.38963
  194. Schlote T., Dannecker G., Thiel H.J. et al. Cyclosporin A in therapy of chronic uveitis in childhood // Ophthalmologe. 1996. Vol. 93. P. 745–748.
  195. Schmeling H., Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis // Rheumathology (Oxford). 2005. Vol. 44, N 8.
    P. 1008–1011.
  196. Scrivo R., Spadaro A., Spinelli F.R. et al. Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al // Arthritis Rheum. 2008. Vol. 58. P. 1555–1556.
  197. Shakoor A., Esterberg E., Acharya N.R. Recurrence of uveitis after discontinuation of infliximab // Ocul. Immunol. Inflamm. 2014. Vol. 22. P. 96–101.
  198. Sharma P.K., Markov G.T., Bajwa A., Foster C.S. Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis // Retina. 2015. Vol. 35, N 12. P. 2641–2646.
  199. Shoenfeld Y., Lev S. et al. Features associated with epilepsy in the antiphospholipid syndrome // J. Rheumatol. 2004. Vol. 31. P. 1344–1348.
  200. Sieper J., Koenig A., Baumgartner S. et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials // Ann. Rheum. Dis. 2010. Vol. 69, N 1. P. 226–229.
  201. Sims J. Scleritis: presentations, disease associations and management // Postgrad. Med. J. 2012. Vol. 88. P. 713–718.
  202. Smith J.A., Thompson D.J., Whitcup S.M. et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis // Arthritis Rheum. 2005. Vol. 53. P. 18–23.
  203. Smith J.R., Rosenbaum J.T. Management of uveitis // Arthritis Rheum. 2002. Vol. 46, N 2. P. 309–318.
  204. Spencer D.G., Hick H.M., Dick W.C. Ankylosing spondylitis — the role of HLA-B27 homozygosity // Tissue Antigens. 1979. Vol. 14, N 5. P. 379–384.
  205. Stone J.H., Tuckwell K., Dimonaco S. et al. Efficacy and safety of tocilizumab in patients with giant cell arteritis: primary and secondary outcomes from a phase 3, randomized, double-blind, placebo-controlled trial // Arthritis Rheumatol. 2016. Vol. 68, suppl. 10. Abstr. 911.
  206. Suhler E.B., Lim L.L., Beardsley R.M. et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical. trial // Ophthalmology. 2014. Vol. 121. P. 1885–1891.
  207. Susac J.O., Hardman J.M., Selhorst J.B. Microangiopathy of the brain and retina // Neurology. 1979. Vol. 29, N 3. P. 313-316. DOI: https://doi.org/10.1212/WNL.29.3.313
  208. Suvajac G., Stojanovich L., Milenkovich S. Ocular manifestations in antiphospholipid syndrome // Autoimmun. Rev. 2007. Vol. 6, N 6. P. 409–414.
  209. Sykes M., Hamilton L., Jones C., Gaffney K. Prevalence of axial spondyloarthritis in patients with acute anterior uveitis: a cross-sectional study utilising MRI // RMD Open. 2018. Vol. 4, N 1. Article ID e000553. DOI: https://doi.org/10.1136/rmdopen-2017-000553
  210. Taban M., Dupps W.J., Mandtll B., Perez V.L. Etanercept (embrel)-associated inflammatory eye disease: case report and review of the literature // Ocul. Immunol. Inflamm. 2006. Vol. 14, N 3. P. 145–150.
  211. Takeuchi M., Kezuka T., Sugita S. et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behcet’s disease: a multicenter study // Ophthalmology. 2014. Vol. 121, N 10. P. 1877–1884.
  212. Tanaka R., Kaburaki T., Nakahara H., Komae K. Ocular inflammation associated with relapsing polychondritis in Japanese patients: a review of 11 patients // Int. Ophthalmol. 2019. Vol. 39, N 11. P. 2649–2659. DOI: https://doi.org/10.1007/s10792-019-01114-8
  213. Tappeiner C., Mesquida M., Adan A. et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis // J. Rheumatol. 2016. Vol. 43. P. 2183–2188.
  214. Tappeiner C., Roesel M., Heinz C. et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis // Eye. 2009. Vol. 23. P. 1192–1198.
  215. Taurog J.D. The role of HLA-B27 in spondyloarthritis // J. Rheumatol. 2010. Vol. 37, N 12. P. 2606–2616. DOI: https://doi.org/10.3899/jrheum.100889
  216. Toyos R., Toyos M., Willcox J., Mulliniks H. Hoover evaluation of the safety and efficacy intense pulsed light treatment with meibomian gland expression of the upper eyelids for dry eye disease // J. Photobiomodul. Photomed. Laser Surg. 2019. Vol. 37, N 9. P. 527–531. DOI: https://doi.org/10.1089/photob.2018.4599 Epub 2019 Jul 29.
  217. Tran T.M., Satumira N., Dorris M.L. et al. HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP // J. Immunol. 2004. Vol. 172, N 8. P. 5110–5119. DOI: https://doi.org/10.4049/jimmunol.172.8.5110
  218. Tromp G., Kuivganeimi H., Raphael S. et al. Genetic linkage of familial granulomatosis, inflammatory arthritis, skin rash, and uveitis to chromosome 16 // Am. J. Hum. Genet. 1996. Vol. 59, N 5. P. 1097–1107.
  219. Tsang A.C., Roth J., Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient // Ocul. Immunol. Inflamm. 2014. Vol. 22. P. 155–157.
  220. Tugal-Tutkun I., Pavesio C., De Cordoue A. et al. Use of gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study // Ocul. Immunol. Inflamm. 2018. Vol. 25. P. 1–11. DOI: https://doi.org/10.1080/09273948.2017.1421233
  221. Tynjälä P., Kotaniemi K., Lindahl P. et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis // Rheumatology. 2008. Vol. 47. P. 339–344.
  222. Uchino Y., Kawakita T., Miyazawa M. et al. Oxidative stress induced inflammation initiates functional decline of tear production // PLoS One. 2012. Vol. 7. Article ID e45805.
  223. Utz V.M., Tang J. Ocular manifestations of the antiphospholipid syndrome // Br. J. Ophthalmol. 2011. Vol. 95, N 4. P. 454–459. DOI: https://doi.org/10.1136/bjo.2010.182857
  224. Uy H.S., Christen W.G., Foster C.S. HLA-B27-associated uveitis and cystoid macular edema // Ocul. Immunol. Inflamm. 2001. Vol. 9, N 3. P. 177–183.
  225. Van Denderen J.C., Visman I.M., Van Breemen J. Adalimumab significantly reduces the recurrence rate of anterior uveitis in patients with ankylosing spondylitis // J. Rheumatol. 2014. Vol. 41, N 9. P. 1843–1848.
  226. Védrine L., Algayres J.P., Coutant G. Giant-cell arteritis // N. Engl. J. Med. 2003. Vol. 348, N 15. P. 1497–1498.
  227. Villiger P., Adler S., Kuchen S. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial // Lancet. 2016. Vol. 387. P. 1921–1927. DOI: https://doi.org/10.1016/S0140-6736(16)00560-2
  228. Vinceneux P. Cogan syndrome // Orphanet Encyclopedia. 2005.
  229. Vishnevskia-Dai V., Chapman J., Sheinfeld R. et al. Susac syndrome: clinical characteristics, clinical classification, and long-term prognosis // Medicine (Baltimore). 2016. Vol. 95, N 43. P. e5223. DOI: https://doi.org/10.1097/MD.0000000000005223
  230. Wakefield D., Di Girolamo N., Thurau S. et al. Scleritis: challenges in immunopathogenesis and treatment // Discov. Med. 2013. Vol. 16. P. 153–157.
  231. Watson P., Hayreh S. Scleritis and episcleritis // Br. J. Ophthalmol. 1976. Vol. 60. P. 163–191.
  232. Wouters C.H., Maes A., Foley K.P., Bertin J. et al. Blau syndrome, the prototypic auto-inflammatory granulomatous disease // Pediatr. Rheumatol. Online J. 2014. Vol. 12. P. 33. DOI: https://doi.org/10.1186/1546-0096-12-33 Epub 2014 Aug 6.
  233. Yamada Y., Sugita S., Tanaka H. et al. Timing of recurrent uveitis in patients with Behcet’s disease receiving infliximab treatment // Br. J. Ophthalmol. 2010. Vol. 95. P. 205–208. DOI: https://doi.org/10.1136/bjo.2009.168856
  234. Yang P., Wan W., Du L. et al. Clinical features of HLA-B27-positive acute anterior uveitis with or without ankylosing spondylitis in a Chinese cohort // Br. J. Ophthalmol. 2018. Vol. 102, N 2. P. 215–219. DOI: https://doi.org/10.1136/bjophtalmol-2016-309499
  235. Yang P.Z., Wang H., Zhang Z. et al. Clinical diagnosis and treatment of uveitis associated with ankylosing spondylitis // Chin. J. Ophthalmol. 2005. Vol. 41, N 6. P. 515–518.
  236. Yazgan S., Celik U., Dogan I. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis // Int. Ophthalmol. 2017. Vol. 37, N 1. P. 139–145.
  237. Yazici H., Pazarli H., Barnes C.G. et al. A controlled trial of azathioprine in Behcet’s syndrome // N. Engl. J. Med. 1990. Vol. 322. P. 281–285. DOI: https://doi.org/10.1056/NEJM199002013220501
  238. Yehudai D., Shoenfeld Y., Toubi E. Looking into the eyes of patients with antiphospholipid syndrome // Clin. Rev. Allergy Immunol. 2007. Vol. 32. P. 192–197.
  239. You C., Sahawneh H.F., Ma L. et al. A review and update on orphan drugs for the treatment of noninfectious uveitis // Clin. Ophthalmol. 2017. Vol. 11. P. 257–265.
  240. Zeidan M.J, Saadoun D., Garrido M. et al. Behcet’s disease physio-
    pathology: a contemporary review // Autoimmun. Highlights. 2016. Vol. 7, N 1. P. 4. DOI: https://doi.org/10.1007/s13317-016-0074-1
  241. Zeidler H., Amor B. The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress // Ann. Rheum. Dis. 2011. Vol. 70, N 1. P. 1–3. DOI: https://doi.org/10.1136/ard 2010.135645
  242. Zhuang Z., Wang Y., Zhu G. et al. Imbalance of Th17/Treg cells in pathogenesis of patients with human leukocyte antigen B27 associated acute anterior uveitis // Sci. Rep. 2017. Vol. 7. Article ID 40414. DOI: https://doi.org/10.1038/step40414
  243. Zierhut M.. Deuter C., Murray P.I. Classification of uveitis — current guidelines // European Ophthalmic Review. 2007. P. 77–78.
  244. Zlatanović G., Veselinović D., Cekić S. et al. Ocular manifestation of rheumatoid arthritis-different forms and frequency // Bosn. J. Basic Med. Sci. 2010. Vol. 10. P. 323.
  245. Zulian F., Balzarin M., Falcini F. et al. Abatacept for severe anti-tumor necrosis factor a refractory juvenile idiopathic arthritis-related uveitis // Arthritis Care Res. 2010. Vol. 62. P. 821–825.

Для продолжения работы требуется вход / регистрация